A buyout requires a willing party to sell when it comes to buying the whole company. Gerald et al are clearly not willing to sell. Ask yourself why sell if you don't have a product/revenue yet? Why sell if you think you can increase the value of the company through further work and then sell at a greater multiple? Why sell if you think you can control your own destiny through partnership and other funding, especially when you own a large position in the company?
As for investing in the company and buying stock, we all know why large institutions such as mutual funds et al don''t buy this right now.
Pretty simple analysis in my opinion.
There were only 10,000 or so short shares as of 11/15. I think this claim that shorts are going to get killed really is a non event when there are 500 million shares OS
Dear Mr. MacKay,
With the price you charge, what is your recovery period of your costs? Why does your product cost so much? Just because you haven't continued the innovation to bring your costs down and increase your margins over time doesn't mean the American people should continue to pay the excessive price for your product. You have shipped 500,000 units. We can not believe that your markup for those units is such that you have not recovered your costs for that product. Innovate or die.
Use their greed to your own advantage. They are looking for a big payoff. Buy on weakness and hold. Their own greed can't stop revenues to increase from this CMS outcome, so the valuation will move up on the stock. If they are forcing the price down, use it.
$330 per treatment more in revenue to the top line. Margin expansion should be huge.
It will be interesting to see how the next few months play out, especially given the relatively low float and OS counts even after execution of the latest financial obligation/notes issuance.
First you bash someone about their opinion who is a pro and then come looking for an opinion from a random board. Welcome to ignore world.
So I got a negative post for putting out fact while some turd comes in and throws around a BS allegation. All you need to know.
He didn't. He analyzes based on circumstances. He wrote one article, making a few assumptions about what could happen. FDA threw a curveball and the market adjusted as did JN based on the new info. Being a true analyst he doesn't/can't take positions in what he covers based on Zacks policy.
He is a lying POS. There is no short interest of any consequence in this stock. Just day traders/swing traders.
I say by noon.
Depends. If this gets to the $0.20 level then a R/S 25 to 1 is all that is needed. That could happen with successful Lympro launch later next year.
Any specific catalyst today or just the pop off of Fox?